The Mindbloom Method is clinically validated across the 3 largest peer-reviewed studies of ketamine therapy ever published.
All three showed stellar outcomes across anxiety, depression, PTSD, and more.
Mindbloom’s research archive
At-home, telehealth-supported ketamine therapy for veterans with depression, anxiety, and PTSD: Findings from a real-world, observational study
Mindbloom is committed to advancing psychedelic science, with the largest body of research of any ketamine therapy provider following more than 11,000 clients.
Symptom improvement
reported symptom improvement in anxiety & depression1
reported meaningful PTSD symptom improvement2
with suicidal thoughts reported them fully resolved within program completion1
Speed to results
Not only does our at-home ketamine program greatly reduce feelings of anxiety and depression, it does so in hours or days—not months.
Mindbloom1
Hours to days
Tradtional SSRIs3
4-8 weeks
With traditional treatments, people might not notice improvements for up to 2 months—that is, if they see improvements at all. Because of ketamine’s fast-acting nature, most Mindbloom clients report symptom relief after just 4 sessions, and some after their very first session.
Side effects
experienced no side effects with Mindbloom treatment1
Many come to Mindbloom frustrated by side effects of their SSRIs (weight gain, emotional flatness, loss of libido). Our peer-reviewed studies demonstrate the high tolerability profile of this treatment. The mild effects that may occur typically clear within hours. That's why people finish their programs, and why Mindbloom’s care model actually works.
Treatment comparisons
When compared to studies of alternative treatments, Mindbloom’s symptom improvements were stronger and achieved in just 4 weeks vs 2+ months.
Sleep
The largest ketamine sleep analysis to date saw clients report significant improvement—better than Ambien, trazodone, melatonin, and CBT for insomnia—often visible after just 2 Mindbloom sessions.7
saw clinically meaningful improvement in sleep
Veterans
The largest evaluation of ketamine therapy in veterans ever published saw tremendous outcomes across anxiety, depression, and PTSD.8
Ketamine has been used safely and effectively for mental health for 20+ years.
With over 300 major studies conducted across 50+ institutions, clinical research continues to demonstrate that ketamine can be successfully used to treat mental health conditions and their symptoms.
Safety, effectiveness and tolerability of sublingual ketamine in depression and anxiety: A retrospective study of off-label, at-home use
This study assessed the effectiveness and safety of self-administration of off-label, SL, rapid dissolve ketamine tablets (RDT) at-home for depression and anxiety.
Intramuscular ketamine vs. escitalopram and aripiprazole in acute and maintenance treatment of patients with treatment-resistant depression: A randomized double-blind clinical trial
This study can potentially yield evidence on the use of IM ketamine in the treatment of depressive disorders as an ultra-rapid low-cost therapy associated with less patient discomfort and reduced use of medical resources, and can elucidate long-term effects on different outcomes, such as neuropsychological aspects.
Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders
This systematic review and meta-analysis collected efficacy, safety, and tolerability data for ketamine as a treatment for anxiety spectrum disorders.
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation
Review article synthesizing research on the efficacy, safety, and clinical use of ketamine and esketamine in treating treatment-resistant major depressive disorder.
You deserve proof, not promises.
Hull TD, et al. Journal of Affective Disorders (2022). https://doi.org/10.1016/j.jad.2022.07.004.
Parks AC, et al. Journal of Medical Internet Research (2026). https://doi.org/10.2196/92647.
Trivedi M,. et al. American Journal of Psychiatry (2006). https://doi.org/10.1176/appi.ajp.163.1.28.
Cuijpers P, et al. Acta Psychiatrica Scandinavica (2021). https://doi.org/10.1111/acps.13335.
McInnes L. A., et al. Journal of Affective Disorders (2022). https://doi.org/10.1016/j.jad.2021.12.097.
Mathai DS, et al. Journal of Affective Disorders (2024). https://doi.org/10.1016/j.jad.2024.05.131
Swain et al., Research Square (2026). https://doi.org/10.21203/rs.3.rs-9553669/v1.
Lutz et al., Manuscript in preparation (2026)
